Kopp Reinhard, Stachowski Lukas, Puippe Gilbert, Zimmermann Alexander, Menges Anna-Leonie
Department of Vascular Surgery, University Hospital Zurich, 8091 Zurich, Switzerland.
Section of Vascular and Endovascular Surgery, University Hospital Regensburg, 93053 Regensburg, Germany.
J Clin Med. 2025 Jan 3;14(1):234. doi: 10.3390/jcm14010234.
: The parallel stent graft endovascular aortic repair (PGEVAR) technique is an off-the-shelf option used for elective complex abdominal aortic aneurysm repair with acceptable outcome results, as reported so far. The PGEVAR technique, using chimney or periscope parallel grafts, can also be used for patients with ruptured complex abdominal aortic aneurysms. However, only few data about the mid- to long-term outcomes are available. : Data from patients treated between August 2009 and July 2023 with the PGEVAR technique for ruptured complex abdominal aortic aneurysms were analyzed. The endpoints of this study were primary and secondary technical success, perioperative mortality, rate of proximal type 1a (gutter) endoleaks (T1aEL), and overall and aneurysm-related survival. Secondary endpoints were major adverse events, durability of parallel grafts, and factors associated with overall survival. : Twenty patients (mean age: 77 ± 9 y; 18 male) with ruptured complex abdominal aortic aneurysm were treated, receiving PGEVAR for ruptured juxtarenal (n = 11), suprarenal (n = 7), or distal thoracoabdominal Crawford IV aortic aneurysms (n = 2) with a mean diameter of 82 ± 18 mm (range 59-120). The patients had PGEVAR with implantation of 39 parallel grafts (1.95 PGs per patient; 23 chimney and 16 periscope) for revascularization of the celiac artery (n = 3), superior mesenteric artery (n = 9), and renal arteries (n = 27). Three patients had delayed PG implantation within 10 days. Primary technical success was 15/20 (75%) with five patients having an early proximal T1aEL, three of them having successful reintervention (secondary success rate: 18/20; 90%), with no persistent bleeding. Two patients had late T1aELs. The presence of an early T1aEL was related to the number of PGs (≥2) implanted ( = 0.038) or insufficient aortic SG oversizing ( = 0.038). In-hospital mortality was 1/20 (5%). Perioperative mortality up to 32 days was 3/20 (15%), with two further late aneurysm-related deaths and eight late aneurysm-unrelated deaths (overall mortality 13/20; 65%) during follow-up (median 34 months; range 1-115). Major adverse events were observed in 11 (55%) patients. Secondary parallel stent graft patency at 1 and 3 years was 97.4 and 94.1%. During follow-up, aneurysm sac behavior was determined in 19 patients, which showed diameter progression (n = 3), stable aneurysm disease (n = 3), and aneurysm diameter regression in 13 (68.4%) patients. Overall survival was 75% after 1 year, and 53% and 22% after 3 and 5 years. Factors associated with overall long-term survival were age < 80 years ( = 0.037), juxtarenal aneurysms ( = 0.023), the absence of major adverse events ( = 0.025), and aneurysm sac regression ( = 0.003). : Treatment of ruptured complex abdominal aortic aneurysm with the PGEVAR technique is associated with acceptable perioperative and long-term outcomes with high PG patency rates. Early proximal T1aELs are observed with a relevant frequency, requiring early reintervention with successful sealing of most relevant endoleaks. To note, limitation of the number of parallel stent grafts implanted at the proximal aortic sealing sites, sufficient PG sealing length, and adequate main aortic SG oversizing are most relevant to avoid T1a (gutter) ELs. The selection of juxtarenal aortic aneurysms and evidence for aneurysm sac diameter regression after PGEVAR had a prognostic impact.
目前报道显示,平行支架型血管腔内主动脉修复术(PGEVAR)是一种用于择期复杂性腹主动脉瘤修复的现成方法,其治疗效果可接受。使用烟囱式或潜望镜式平行移植物的PGEVAR技术,也可用于治疗破裂性复杂性腹主动脉瘤患者。然而,关于中长期治疗效果的数据较少。
分析了2009年8月至2023年7月期间采用PGEVAR技术治疗破裂性复杂性腹主动脉瘤患者的数据。本研究的终点指标为初次和二次技术成功率、围手术期死亡率、近端1a型(肠沟)内漏发生率(T1aEL)以及总体生存率和与动脉瘤相关的生存率。次要终点指标为主要不良事件、平行移植物的耐久性以及与总体生存率相关的因素。
20例(平均年龄:77±9岁;18例男性)破裂性复杂性腹主动脉瘤患者接受了治疗,因肾旁(n = 11)、肾周(n = 7)或远端胸腹主动脉Crawford IV型动脉瘤破裂(n = 2)接受PGEVAR治疗,平均直径为82±18mm(范围59 - 120mm)。患者接受PGEVAR治疗时植入了39个平行移植物(每位患者1.95个移植物;23个烟囱式和16个潜望镜式),用于腹腔干动脉(n = 3)、肠系膜上动脉(n = 9)和肾动脉(n = 27)的血运重建。3例患者在术后10天内延迟植入平行移植物。初次技术成功率为15/20(75%),5例患者出现早期近端T1aEL,其中3例成功进行了再次干预(二次成功率:18/20;90%),且无持续性出血。2例患者出现晚期T1aEL。早期T1aEL的出现与植入的平行移植物数量(≥2个)(P = 0.038)或主动脉覆膜支架尺寸不足(P = 0.038)有关。住院死亡率为1/20(5%)。至32天的围手术期死亡率为3/20(15%),随访期间(中位时间34个月;范围1 - 115个月)又有2例晚期与动脉瘤相关的死亡和8例晚期与动脉瘤无关的死亡(总体死亡率13/20;65%)。11例(55%)患者出现主要不良事件。1年和3年时平行支架型移植物的通畅率分别为97.4%和94.1%。随访期间,对19例患者的动脉瘤囊情况进行了评估,结果显示动脉瘤直径进展(n = 3)、动脉瘤病情稳定(n = 3)以及13例(68.4%)患者的动脉瘤直径缩小。1年后总体生存率为75%,3年和5年后分别为53%和22%。与总体长期生存率相关的因素包括年龄<80岁(P = 0.037)、肾旁动脉瘤(P = 0.023)、无主要不良事件(P = 0.025)以及动脉瘤囊缩小(P = 0.003)。
采用PGEVAR技术治疗破裂性复杂性腹主动脉瘤,围手术期和长期治疗效果可接受,平行移植物通畅率高。早期近端T1aEL的发生率较高,需要早期再次干预以成功封闭大多数相关内漏。需要注意的是,限制在近端主动脉封闭部位植入的平行支架型移植物数量、足够的平行移植物封闭长度以及适当扩大主动脉覆膜支架尺寸对于避免T1a(肠沟)内漏最为重要。肾旁主动脉瘤的选择以及PGEVAR术后动脉瘤囊直径缩小的证据具有预后意义。